Internal and Emergency Medicine

, Volume 3, Issue 1, pp 53–56

Rimonabant for overweight and “metabolic syndrome”: the attempt to supersize disease and risk by pharmaceutical marketing

  • Rita Banzi
  • Lorenzo Moja
  • Ivan Moschetti
  • Alessandro Liberati
  • Gian Franco Gensini
  • Roberto Gusinu
  • Andrea A. Conti
CE - Cochrane's Corner

References

  1. 1.
    Curioni C, Andre C (2006) Rimonabant for overweight or obesity. Cochrane Database Syst Rev, CD006162Google Scholar
  2. 2.
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389–1397PubMedCrossRefGoogle Scholar
  3. 3.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775PubMedCrossRefGoogle Scholar
  4. 4.
    Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368:1660–1672PubMedCrossRefGoogle Scholar
  5. 5.
    Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121–2134PubMedCrossRefGoogle Scholar
  6. 6.
    Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. PLoS Med 4:e184PubMedCrossRefGoogle Scholar
  7. 7.
    Djulbegovic B et al (2000) The uncertainty principle and industry-sponsored research. Lancet 356:635–638PubMedCrossRefGoogle Scholar
  8. 8.
    Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173PubMedCrossRefGoogle Scholar
  9. 9.
    NHI Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/ob_home.htm
  10. 10.
    EMEA (2006) Guideline on clinical investigation of medicinal product used in weight control. http://www.emea.europa.eu/pdfs/human/ewp/028196en.pdf
  11. 11.
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194–1199PubMedCrossRefGoogle Scholar
  12. 12.
    EMEA European Public Assessment Report (EPAR). http://www.emea.europa.eu/humandocs/Humans/EPAR/acomplia/acomplia.htm. Last accessed Jan 2007
  13. 13.
  14. 14.
    Reaven GM, Chen YD (1988) Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 4:639–652PubMedCrossRefGoogle Scholar
  15. 15.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428PubMedCrossRefGoogle Scholar
  16. 16.
    Gale EA (2005) The myth of the metabolic syndrome. Diabetologia 48:1679–1683PubMedCrossRefGoogle Scholar
  17. 17.
    Heath I (2006) Combating disease mongering: daunting but nonetheless essential. PLoS Med 3:e146PubMedCrossRefGoogle Scholar
  18. 18.
    Moynihan R, Henry D (2006) The fight against disease mongering: generating knowledge for action. PLoS Med 3:e191PubMedCrossRefGoogle Scholar
  19. 19.
    Mintzes B (2006) Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 3:e198PubMedCrossRefGoogle Scholar
  20. 20.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–28PubMedCrossRefGoogle Scholar
  21. 21.
    Zimmet PZ, Alberti G (2005) Medscape diabetes & endocrinology. 7(2). Available at http://www.medscape.com/viewarticle/514211. Accessed on January 31, 2008
  22. 22.
    Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet 370:1706–1713PubMedCrossRefGoogle Scholar
  23. 23.
    Moynihan R, Heath I, Henry D (2002) Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324:886–891PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2008

Authors and Affiliations

  • Rita Banzi
    • 1
  • Lorenzo Moja
    • 1
  • Ivan Moschetti
    • 1
  • Alessandro Liberati
    • 1
  • Gian Franco Gensini
    • 2
  • Roberto Gusinu
    • 3
  • Andrea A. Conti
    • 4
  1. 1.Italian Cochrane CentreMario Negri Institute for Pharmacological ResearchMilanItaly
  2. 2.Department of Critical Care Medicine and SurgeryUniversity of Florence and Azienda Ospedaliero-Universitaria CareggiFlorenceItaly
  3. 3.DAI Cardiologico e dei Vasi, Azienda Ospedaliero-Universitaria CareggiFlorenceItaly
  4. 4.Department of Critical Care Medicine and SurgeryUniversity of Florence and Don Carlo Gnocchi Foundation IRCCSFlorenceItaly

Personalised recommendations